Trial Profile
Cross-immunogenicity between infliximab antibodies in Remicade-treated patients with IBD and the infliximab biosimilar Remsima
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Pharmacodynamics
- 06 Nov 2015 New trial record